RHYTHM PHARMACEUTICALS, INC.

RYTM · Biotech · Nasdaq · As of 10 Sep 2026

FundamentalsNot enough data yet
ValueNot enough data yet
News flowBalanced
MomentumBalanced
SafetyBalanced

Overall confidence 41/100 — few inputs available yet

Fundamental score not available. AIR's fundamental engine is built for businesses with established revenue and cash flow; biotech financial profiles — often R&D-heavy or pre-revenue — don't yet fit the measures it requires. AIR still assesses this company on discovery, market confirmation and risk, at reduced overall confidence.

Discovery Gap: High (33/100) · Gap confidence 64/100Filings show more traction than the tape reflects.

This month at a glance

AIR Score™ change: +1Moved up +1 on new evidence.

Cycle window9 Sep 2026 → 10 Sep 2026

Momentum+1Contributed positively to the latest score.

Evidence timeline

[8-K 8.01] RHYTHM PHARMACEUTICALS, INC. — Other EventsSEC · SEC EDGAR
Aug 4, 2026 · 8-K
[8-K 2.02] RHYTHM PHARMACEUTICALS, INC. — Results of Operations and Financial ConditionSEC · SEC EDGAR
Aug 4, 2026 · 8-K
[8-K 8.01] RHYTHM PHARMACEUTICALS, INC. — Other EventsSEC · SEC EDGAR
Jun 13, 2026 · 8-K
[8-K 2.02] RHYTHM PHARMACEUTICALS, INC. — Results of Operations and Financial ConditionSEC · SEC EDGAR
May 5, 2026 · 8-K
[8-K 5.02] RHYTHM PHARMACEUTICALS, INC. — Departure/Election of Directors or Principal OfficersSEC · SEC EDGAR
Apr 1, 2026 · 8-K
[8-K 8.01] RHYTHM PHARMACEUTICALS, INC. — Other EventsSEC · SEC EDGAR
Mar 26, 2026 · 8-K
[8-K 8.01] RHYTHM PHARMACEUTICALS, INC. — Other EventsSEC · SEC EDGAR
Mar 19, 2026 · 8-K
[FDA supplemental_efficacy_approval] RHYTHM PHARMACEUTICALS, INC. — IMCIVREE (NDA213793/9) — Supplemental efficacy approval (new indication / label expansion)FDA · openFDA drugsfda
Mar 19, 2026 · Supplemental efficacy approval (new indication / label expansion)
[8-K 8.01] RHYTHM PHARMACEUTICALS, INC. — Other EventsSEC · SEC EDGAR
Mar 16, 2026 · 8-K
[8-K 8.01] RHYTHM PHARMACEUTICALS, INC. — Other EventsSEC · SEC EDGAR
Mar 2, 2026 · FORM 8-K
[8-K 2.02] RHYTHM PHARMACEUTICALS, INC. — Results of Operations and Financial ConditionSEC · SEC EDGAR
Feb 26, 2026 · 8-K
[8-K 8.01] RHYTHM PHARMACEUTICALS, INC. — Other EventsSEC · SEC EDGAR
Jan 9, 2026 · 8-K

Ask AIR

What would change our view

A weaker balance sheet in the next filing cycle, a material regulatory setback, or attention arriving — which closes the gap by design would move the score, and the page would show which one did.

Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.